Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.52 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.49 |
| ▸ | ALDH1A3 | P47895 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | STS | P08842 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6386806 | 0.93 | ALDH1A1 (0.46) | ALDH1A1CYP2A6SMN1; SMN2LMNAMAPT | |
| SCHEMBL16429677 | 0.83 | ALDH1A1 (0.51) | ALDH1A1CYP2A6SMN1; SMN2LMNAMAPT | |
| SCHEMBL14369374 | 0.80 | CHRNA7 (0.50) | ALDH1A1SMN1; SMN2MAPTHPGDKMT2A | |
| SCHEMBL4131738 | 0.79 | ALDH1A1 (0.60) | ALDH1A1CYP2A6SMN1; SMN2LMNAMAPT | |
| SCHEMBL17816428 | 0.79 | ALDH1A1 (0.44) | ALDH1A1CYP2A6SMN1; SMN2LMNAMAPT | |
| SCHEMBL16415681 | 0.79 | ALDH1A1 (0.51) | ALDH1A1CYP2A6SMN1; SMN2LMNAMAPT | |
| SCHEMBL342467 | 0.77 | NQO1 (0.64) | ALDH1A1CYP2A6SMN1; SMN2LMNAMAPT | |
| SCHEMBL851166 | 0.76 | ALDH1A1 (0.66) | ALDH1A1CYP2A6SMN1; SMN2LMNAMAPT | |
| SCHEMBL8754251 | 0.76 | ALDH1A1 (0.56) | ALDH1A1CYP2A6SMN1; SMN2LMNAMAPT | |
| SCHEMBL4964476 | 0.75 | TP53 (0.46) | ALDH1A1LMNAMAPTHPGDKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9828393-B2 | Silylalkyloxyaryl compounds and methods for treating cancer | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2017-11-28 | — | — | US | disclosed |
| WO-2015013322-A1 | SILYLALKYLOXYARYL COMPOUNDS AND METHODS FOR TREATING CANCER | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2015-01-29 | — | — | WO | disclosed |
| US-20080171802-A1 | Methyltrialkylsilanes containing a cinnamate, cinnamamide, benzalmalonamide or benzalmalonate function and photostabilizing methods | L'OREAL (FR) | 2008-07-17 | — | — | US | disclosed |
| US-7354571-B2 | Photoprotective compositions comprising methyltrialkylsilanes containing a cinnamate, cinnamamide, benzalmalonamide or benzalmalonate function | L'OREAL (FR) | 2008-04-08 | — | — | US | disclosed |
| EP-1594880-B1 | PHOTOPROTECTIVE COMPOSITIONS BASED ON METHYLTRIALKYLSILANES CONTAINING A CINNAMATE, CINNAMAMIDE, BENZALMALONAMIDE OR BENZALMALONATE FUNCTION | OREAL (FR) | 2008-03-19 | — | — | EP | disclosed |
| US-20060018848-A1 | Photoprotective compositions comprising methyltrialkylsilanes containing a cinnamate, cinnamamide, benzalmalonamide or benzalmalonate function | L'OREAL (FR) | 2006-01-26 | — | — | US | disclosed |
| EP-1594880-A1 | PHOTOPROTECTIVE COMPOSITIONS BASED ON METHYLTRIALKYLSILANES CONTAINING A CINNAMATE, CINNAMAMIDE, BENZALMALONAMIDE OR BENZALMALONATE FUNCTION | L'OREAL (FR) | 2005-11-16 | — | — | EP | disclosed |
| WO-2004067539-A1 | PHOTOPROTECTIVE COMPOSITIONS BASED ON METHYLTRIALKYLSILANES CONTAINING A CINNAMATE, CINNAMAMIDE, BENZALMALONAMIDE OR BENZALMALONATE FUNCTION | L'OREAL (FR) | 2004-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080171802-A1 | Methyltrialkylsilanes containing a cinnamate, cinnamamide, benzalmalonamide or benzalmalonate function and photostabilizing methods | KCNN1, KCNN2, CMBL | ALDH1A1 828/4885CYP2A6 1369/4885SMN1; SMN2 1147/4885 |
| US-20060018848-A1 | Photoprotective compositions comprising methyltrialkylsilanes containing a cinnamate, cinnamamide, benzalmalonamide or benzalmalonate function | TRPM7, TRPM6, KCNN1 | ALDH1A1 636/4885CYP2A6 1561/4885SMN1; SMN2 2056/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.